Hormone Receptor-Positive Breast Carcinoma Clinical Trials

22 recruitingLast updated: June 17, 2026

There are 22 actively recruiting hormone receptor-positive breast carcinoma clinical trials across 20 countries. Studies span Phase 2, Not Applicable, Phase 1, Early Phase 1, Phase 3, Phase 4. Top locations include St Louis, Missouri, United States, Atlanta, Georgia, United States, Seattle, Washington, United States. Updated daily from ClinicalTrials.gov.


Hormone Receptor-Positive Breast Carcinoma Trials at a Glance

22 actively recruiting trials for hormone receptor-positive breast carcinoma are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in St Louis, Atlanta, and Seattle. Lead sponsors running hormone receptor-positive breast carcinoma studies include Emory University, National Cancer Institute (NCI), and Mayo Clinic.

Browse hormone receptor-positive breast carcinoma trials by phase

Treatments under study

About Hormone Receptor-Positive Breast Carcinoma Clinical Trials

Looking for clinical trials for Hormone Receptor-Positive Breast Carcinoma? There are currently 18 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hormone Receptor-Positive Breast Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hormone Receptor-Positive Breast Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Phase 3

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled541 locationsNCT06058377
Recruiting
Phase 1

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled2 locationsNCT07137416
Recruiting
Phase 2

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Triple-Negative Breast CancerHormone Receptor-Positive Breast CancerHormone Receptor-Positive Breast Carcinoma+1 more
Laura Huppert, MD, BA36 enrolled1 locationNCT06224673
Recruiting
Phase 2

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

Advanced Breast CancerHormone Receptor-Positive Breast CarcinomaAdvanced Breast Carcinoma
MedSIR200 enrolled72 locationsNCT06486883
Recruiting
Phase 1

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Colorectal, CancerHormone Receptor-Positive Breast CarcinomaGastric Adenocarcinoma+6 more
Avacta Life Sciences Ltd174 enrolled3 locationsNCT07454642
Recruiting

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

Metastatic Breast CancerHER2-Negative Breast CarcinomaHER2-negative Breast Cancer+6 more
Mayo Clinic100 enrolled1 locationNCT06388122
Recruiting
Phase 1

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Metastatic Breast CancerHER2-negative Breast CancerAdvanced Solid Tumor+6 more
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Not Applicable

Mobile Health for Adherence in Breast Cancer Patients

Breast CarcinomaHER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8+1 more
ECOG-ACRIN Cancer Research Group410 enrolled506 locationsNCT06112613
Recruiting
Phase 2

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaHormone Receptor-Positive Breast Carcinoma+1 more
City of Hope Medical Center43 enrolled6 locationsNCT04305834
Recruiting
Phase 2

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast Carcinoma+3 more
University of Washington60 enrolled2 locationsNCT06179303
Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Ovarian CarcinomaEsophageal CarcinomaGastric Carcinoma+26 more
National Cancer Institute (NCI)1,600 enrolled152 locationsNCT04314401
Recruiting
Phase 2

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
University of Washington40 enrolled1 locationNCT07112053
Recruiting
Phase 1

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell Carcinoma+22 more
Fred Hutchinson Cancer Center25 enrolled1 locationNCT05098210
Recruiting
Phase 4

A Study of Revaree Plus in People With Breast Cancer

Breast CancerStage III Breast CancerHormone Receptor-Positive Breast Cancer+8 more
Memorial Sloan Kettering Cancer Center60 enrolled7 locationsNCT07042581
Recruiting
Not Applicable

Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more
Emory University150 enrolled4 locationsNCT06534125
Recruiting

The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients

Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more
Ohio State University Comprehensive Cancer Center100 enrolled1 locationNCT07341503
Recruiting
Phase 2

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Invasive Breast CancerStage III Breast CancerStage IIB Breast Cancer+4 more
Jonsson Comprehensive Cancer Center88 enrolled9 locationsNCT04553770
Recruiting
Not Applicable

Neoadjuvant Breast Cancer Time Restricted Eating

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+4 more
Thomas Jefferson University55 enrolled1 locationNCT05327608
Recruiting
Phase 2

5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage 0 Breast Cancer AJCC v8+2 more
Mayo Clinic38 enrolled1 locationNCT07044310
Recruiting
Early Phase 1

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+3 more
Emory University40 enrolled4 locationsNCT05464810